A review of the management of antidepressant discontinuation symptoms
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Strong evidence supports the existence of a discontinuation syndrome following the withdrawal of antidepressant medication, particularly second-generation antidepressants. The syndrome is a common phenomenon and guidance as to best avoid the symptoms is essential for both practitioners and patients. The current study reviewed the available literature on the best methods of discontinuation for antidepressants in order to avoid or prevent the occurrence of any unpleasant side effects associated with antidepressant withdrawal. Accordingly, an electronic search of the PubMed/MedLine database and Google Scholar was conducted to find relevant literature published within the last 10 years. From this, 18 related articles were identified; five clinical studies, one case series, one consensus panel’s recommendations and 11 literature reviews. Of the articles reviewed there is a general consensus as to tapering the drug slowly over a period of weeks or months. Also, in those patients who experience severe symptoms the drug should be reinstated and discontinued more gradually. The discontinuation syndrome does not occur as frequently or severely with longer-acting agents such as fluoxetine and therefore it is recommended that switching to this drug prior to withdrawal may be advisable. The articles reviewed also emphasize the need for patient education and reassurance throughout the discontinuation process. One in particular adds that cognitive behavioural therapy may be a useful tool in easing the patients’ distress. However, this review highlights the lack of controlled data to support the available guidelines. Furthermore, the guidance which is available is somewhat conflicting. Research approaches should address this issue as well as develop appropriate methods of withdrawal for specific drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“However, this recommendation is not supported by controlled data, and a few authors even suggested that reinstating the drug may be detrimental and lead to more severe withdrawal.39,45”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [39]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These results are consistent with the findings of a previous review reporting consensus about tapering antidepressants slowly over a period of weeks or months to avoid withdrawal symptoms (Wilson 2015).”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Wilson 2015
The cited source says what the claim attributes to it.
In the citing paper
“The characteristics of the discontinuation syndrome have been linked to the half-life of a given SSRI, which can explain the low levels of fluoxetine discontinuation syndrome here identified (Wilson and Lader, 2015)”
From Is There a Potential of Misuse for Venlafaxine and Bupropion? (2018) · cites this paper as Wilson and Lader, 2015
In the citing paper
“However, this recommendation is not supported by controlled data, and a few authors even suggested that reinstating the drug may be detrimental and lead to more severe withdrawal.39,45”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [39]
In the citing paper
“As PWS from antidepressants has been so poorly recognized, the literature is largely silent about its treatment.35,39”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [39]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cohen, L. S. (2006) · JAMA · doi:10.1001/jama.295.5.499 · Cited by 1,031
Depression: A Global Public Health Concern: (517532013-004)
Marcus, M., Yasamy, M. T., van Ommeren, M. V., Chisholm, D., & Saxena, S. (2012) · PsycEXTRA Dataset · doi:10.1037/e517532013-004 · Cited by 985
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759 · cited 2×
“At present, the most recent antidepressant guidelines advise this method and recommend a minimum period of a 4-week taper following long-term treatment, preferably over months for a planned withdrawal of antidepressant medication [Cleare et al. 2015].”
BackgroundBirth Outcomes in Pregnant Women Taking Fluoxetine
Chambers, C. D., Johnson, K. A., Dick, L. M., Felix, R. J., & Jones, K. L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351402 · Cited by 735
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Initiatives to Promote the Discovery of Drugs to Improve Cognitive Function in Severe Mental Illness
Marder, S. R. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0706e03 · Cited by 218
Discontinuation Symptoms After Treatment With Serotonin Reuptake Inhibitors: A Literature Review
Zajecka, J., Tracy, K. A., & Mitchell, S. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0702 · Cited by 209 · cited 1×
“In 1997, Zajecka and colleagues defined the SSRI discontinuation syndrome as a cluster of symptoms following the discontinuation of a SSRI, not due to other factors [Zajecka et al. 1997].”
BackgroundSelective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria.
(2000) · PubMed Central · Cited by 207
Montgomery, S. A., Kennedy, S. H., Burrows, G. D., Lejoyeux, M., & Hindmarch, I. (2004) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000137184.64610.c8 · Cited by 196
Offidani, E., Guidi, J., Tomba, E., & Fava, G. A. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000353198 · Cited by 166 · cited 1×
“In a comparison between the withdrawal reactions of patients treated with benzodiazepines and antidepressant medication for panic disorder, Offidani and colleagues found both classes of drugs to be associated with the same type of problem upon discontinuation [Offidani et al. 2013].”
BackgroundDiscontinuation symptoms in depression and anxiety disorders
Baldwin, D. S., Montgomery, S. A., Nil, R., & Lader, M. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705006358 · Cited by 140
Self-citationAntidepressant Discontinuation Syndrome
(2017) · The SAGE Encyclopedia of Abnormal and Clinical Psychology · doi:10.4135/9781483365817.n77 · Cited by 134
Illness risk following rapid versus gradual discontinuation of antidepressants
Baldessarini, R. J., Tondo, L., Ghiani, C., & Lepri, B. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09060880 · Cited by 123 · cited 1×
“They also add that illness latency after discontinuing antidepressants was not related to duration of treatment or dose [Baldessarini et al. 2010].”
BackgroundComorbid Schizophrenia and Substance Abuse
Green, A. I., & Brown, E. S. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0906e08 · Cited by 112
Recognising and managing antidepressant discontinuation symptoms
Haddad, P. M., & Anderson, I. M. (2007) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.105.001966 · Cited by 109
Renoir, T. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00045 · Cited by 107 · cited 3×
“In 2013, Renoir stated that the existence of a discontinuation syndrome had been confirmed by a number of well-controlled studies [Renoir, 2013].”
BackgroundInfluentialSchatzberg, A. F., Blier, P., Delgado, P. L., Fava, M., Haddad, P. M., & Shelton, R. C. (2006) · PubMed · Cited by 94
van Geffen, E. C. G., Hugtenburg, J. G., Heerdink, E. R., van Hulten, R. P., & Egberts, A. C. G. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0921-x · Cited by 72
Possible Biological Mechanisms of the Serotonin Reuptake Inhibitor Discontinuation Syndrome
Schatzberg, A. F., Haddad, P. M., Kaplan, E. M., Lejoyeux, M., Rosenbaum, J. F., Young, A. H., & Zajecka, J. (1997) · The Journal of Clinical Psychiatry · Cited by 69
Schatzberg, A. F., Haddad, P. M., Kaplan, E. M., Lejoyeux, M., Rosenbaum, J. F., Young, A. H., & Zajecka, J. (1997) · PubMed · Cited by 61
Focus on: antidepressant prescribing trends in the prescribing of antidepressants in primary care
Spence, R., Roberts, A. P., Ariti, C. A., & Bardsley, M. (2014) · Middlesex University Research Repository (Middlesex University Of London) · Cited by 61
The nature of the discontinuation syndrome associated with antidepressant drugs.
Shelton, R. C. (2006) · PubMed · Cited by 60
Galbally, M., Lewis, A. J., Lum, J., & Buist, A. (2009) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670903107583 · Cited by 59 · cited 1×
“1996] and has since been replicated in a number of studies and has been found with other classes of antidepressants [Galbally et al. 2009].”
ResultHimei, A., & Okamura, T. (2006) · CNS Drugs · doi:10.2165/00023210-200620080-00005 · Cited by 56 · cited 6×
“In addition, Himei and Okamura found that those patients who had experienced adverse symptoms during the early phases of treatment were more likely to suffer from a discontinuation syndrome upon withdrawal and therefore should be monitored closely during discontinuation [Himei and Okamura, 2006].”
BackgroundInfluentialHaddad, P. M., Pal, B. R., Clarke, P., Wieck, A., & Sridhiran, S. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105056554 · Cited by 51 · cited 2×
“It has also been suggested that they may be the result of other causes as antenatal depression is associated with poor maternal health behaviours [Haddad et al. 2005].”
BackgroundPhysiologic mechanisms underlying the antidepressant discontinuation syndrome.
Blier, P., & Tremblay, P. (2006) · PubMed · Cited by 49
The use of antidepressants in clinical practice: focus on agomelatine
McAllister‐Williams, R. H., Baldwin, D. S., Haddad, P. M., & Bazire, S. (2010) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1094 · Cited by 48
A Consensus Statement for Safety Monitoring Guidelines of Treatments for Major Depressive Disorder
Dodd, S., Malhi, G. S., Tiller, J., Schweitzer, I., Hickie, I., Khoo, J. P., Bassett, D. L., Lyndon, B., Mitchell, P. B., Parker, G., et al. (2011) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048674.2011.595686 · Cited by 45
Guidance for the discontinuation or switching of antidepressant therapies in adults
Ogle, N. R., & Akkerman, S. R. (2013) · Journal of Pharmacy Practice · doi:10.1177/0897190012467210 · Cited by 45 · cited 13×
“Tapering schedules Most articles reviewed agree that tapering is unnecessary for patients who have been taking an antidepressant for 4 weeks or less as this is insufficient time to develop a withdrawal reaction [Ogle and Akkerman, 2013; Haddad and Anderson, 2007; Edwards, 2006].”
BackgroundResultInfluentialPharmacotherapy of Mood Disorders and Treatment Discontinuation
LADER, M. H. (2007) · Drugs · doi:10.2165/00003495-200767120-00001 · Cited by 42
Self-citationAdverse reactions to duloxetine in depression
Bitter, I., Filipovits, D., & Czobor, P. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.582037 · Cited by 38 · cited 7×
“Although there remains some debate as to the biological mechanisms underlying the antidepressant discontinuation syndrome, there is substantial agreement that it can occur following the withdrawal of any antidepressant and is a common phenomenon amongst a wide range of antidepressants including TCAs, MAOIs, and SSRIs,…”
BackgroundInfluentialGreen, B. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.554534 · Cited by 35 · cited 3×
“Some reports claim that some novel antidepressant drugs, such as agomelatine which possesses agonist properties at the melatonin MT1 and MT2 receptors and which acts as an antagonist at the 5-HT3 receptor, do not exhibit a discontinuation syndrome upon withdrawal despite having a relatively short half-life [Green, 201…”
BackgroundInfluentialPotential Adverse Effects of Discontinuing Psychotropic Drugs: Part 2: Antidepressant Drugs
(2010) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20100527-98 · Cited by 35 · cited 1×
“Understanding the particular pharmacology of different antidepressant drugs can help explain the symptoms which arise upon discontinuation [Howland, 2010].”
BackgroundShock‐Like Sensations During Venlafaxine Withdrawal
Reeves, R. R., Mack, J. E., & Beddingfield, J. J. (2003) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.5.678.32198 · Cited by 30
Smeraldi, E., & Delmonte, D. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.828690 · Cited by 28 · cited 1×
“Smeraldi and Delmonte warn, however, that when switching from fluvoxamine to agomelatine the inhibition of CYP 450 1A2 and 2C9 by fluvoxamine can increase agomelatine levels if prescribed simultaneously [Smeraldi and Delmonte, 2013]: a 3-day washout period is preferable to avoid this.”
BackgroundPatient information leaflets for antidepressants: Are patients getting the information they need?
Haw, C., & Stubbs, J. H. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.06.034 · Cited by 27 · cited 2×
“According to Haw and Stubbs, of the patient information leaflets available on antidepressants, not all contain a warning or explanation of the symptoms of the discontinuation syndrome or why it is best not to withdraw these medications abruptly and without the supervision of a medical professional [Haw and Stubbs, 201…”
BackgroundAnalysis of benzodiazepine withdrawal program managed by primary care nurses in Spain
Lopez-Peig, C., Mundet, X., Casabella, B., del Val, J. L., Lacasta, D., & Diogene, E. (2012) · BMC Research Notes · doi:10.1186/1756-0500-5-684 · Cited by 25
Hale, T. W., Kendall-Tackett, K., Cong, Z., Votta, R., & McCurdy, F. (2010) · Breastfeeding Medicine · doi:10.1089/bfm.2010.0011 · Cited by 18 · cited 1×
“Another concern is the neonate, as a discontinuation syndrome has also been detected in a small percentage of infants exposed to antidepressants in utero [Hale et al. 2010], particularly with SSRI exposure [Galbally et al.”
BackgroundTapering antidepressants: is 3 months slow enough?
Phelps, J. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.08.035 · Cited by 16 · cited 2×
“The author argues that this period is required for the body to ‘normalize’ during discontinuation and recommend 4 months in order to reduce relapse rates and symptoms associated with drug withdrawal [Phelps, 2011].”
BackgroundDiscontinuation of antidepressant therapy among patients with major depressive disorder
Davé, S., Classi, P., Kim Le, T., Maguire, A., & Ball, S. (2012) · Open Journal of Psychiatry · doi:10.4236/ojpsych.2012.24038 · Cited by 14
Hallucination induced by paroxetine discontinuation in patients with major depressive disorders
Yasui‐Furukori, N., & Kaneko, S. (2011) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2011.02211.x · Cited by 13 · cited 2×
“Others can include paraesthesia, ‘electric-shock’-like sensations, depersonalization and irritability, although there have been some reported cases of discontinuation leading to visual and auditory hallucinations [Yasui-Furugori and Kaneko, 2011] or even resembling a stroke [Reeves et al.”
BackgroundTint, A., Haddad, P. M., & Anderson, I. M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107087488 · Cited by 13 · cited 2×
“2007] and two of the reviewed publications suggest that the half-life of the drug plays a more pivotal role than the taper rate [Tint et al. 2008; Montgomery et al. 2004].”
Background[Taperingstrips for paroxetine and venlafaxine].
Groot, P. C. (2013) · PubMed · Cited by 12
Cognitive Behaviour Therapy for Withdrawal from Antidepressant Medication: A Single Case Series
Cromarty, P., Jonsson, J., Moorhead, S., & Freeston, M. H. (2010) · Behavioural and Cognitive Psychotherapy · doi:10.1017/s1352465810000512 · Cited by 8 · cited 1×
“Similar to the controlled trials reviewed, the case series [Cromarty et al. 2010] is limited in that it reports on a small amount of data, only three cases.”
ResultDiscontinuing an Antidepressant? Tapering Tips to Ease Distressing Symptoms
Muzina, D. J. (2010) · Current psychiatry · Cited by 6
Gradual Dose Reduction and Medication Tapering: A Clinical Perspective
Beier, M. T., & Martin, C. M. (2007) · The Consultant Pharmacist · doi:10.4140/tcp.n.2007.628 · Cited by 6
Discontinuing treatment for psychiatric disorders
Joffe, R. T. (2006) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0601 · Cited by 5
Guide to safely withdrawing antidepressants in primary care
McHugh, B., & Krishnadas, R. (2011) · Prescriber · doi:10.1002/psb.793 · Cited by 5
Antidepressant Tapering: Avoiding Adverse Consequences of Gradual Dose Reduction
Zarowitz, B. J. (2007) · Geriatric Nursing · doi:10.1016/j.gerinurse.2006.12.004 · Cited by 3 · cited 6×
“They also agree that if discontinuation symptoms are severe, the drug should be reintroduced and a slower taper initiated [Ogle and Akkerman, 2013; Lader, 2007; Zarowitz, 2006; Schatzberg et al.”
BackgroundInfluentialGoldstein, R. B., Storch, E. A., Lehmkuhl, H. D., Geffken, G. R., Goodman, W. K., & Murphy, T. K. (2008) · Depression and Anxiety · doi:10.1002/da.20448 · Cited by 3
Depression: current approaches to management in primary care
Reid, I., & Cameron, I. M. (2009) · Prescriber · doi:10.1002/psb.477 · Cited by 3 · cited 4×
“Need for education The majority of the reviewed literature concur that the education of both clinician and patient is key to the process of drug discontinuation [Ogle and Akkerman, 2013; van Geffen et al. 2005; Schatzberg et al. 2006; Haddad and Anderson, 2007; Reid and Cameron, 2009; McHugh and Krishnadas, 2011; Warn…”
BackgroundInfluentialWithdrawing antidepressants: guide to patient management
Edwards, G. (2006) · Prescriber · doi:10.1002/psb.327 · Cited by 1 · cited 5×
“Most articles reviewed agree that tapering is unnecessary for patients who have been taking an antidepressant for 4 weeks or less as this is insufficient time to develop a withdrawal reaction [Ogle and Akkerman, 2013; Haddad and Anderson, 2007; Edwards, 2006].”
BackgroundInfluential
Research works printed but not linked: 4
- Coryell W. (2013) Depressive disorders. Merck Manuals Professional Edition. Available at: http://www.merckmanuals.com/professional/psychiatric_disorders/mood_disorders/depressive_disorders.html#v1028131 (accessed 25 August 2014).
- Gartlehner G., Hansen R., Morgan L., Thaler K., Lux L., Van Noord M., et al. (2011) Second-generation antidepressants in the pharmacologic treatment of adult depression. An update of the 2007 comparative effectiveness review. Comparative Effectiveness Reviews No. 46. [PubMed] [Google Scholar]
- Lieberman J. (2003) History of the use of antidepressants in primary care. Primary care companion. J Clin Psychiatry 5: 6–10. [Google Scholar]
- Wiese B. (2011) Geriatric depression: The use of antidepressants in the elderly. BCMJ 53: 341–347. [Google Scholar]
Cited by
Samal, K., Mahapatra, S., & Hibzur Ali, M. (2022) · Energy Nexus · doi:10.1016/j.nexus.2022.100076 · Cited by 778
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Fava, G. A., Benasi, G., Lucente, M., Offidani, E., Cosci, F., & Guidi, J. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491524 · Cited by 209
The Serotonin Syndrome: From Molecular Mechanisms to Clinical Practice
Francescangeli, J., Karamchandani, K., Powell, M., & Bonavia, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092288 · Cited by 159
“Antidepressant withdrawal syndrome is typically associated with second-generation antidepressants [17], although it can also occur with SSRIs and tricyclic antidepressants (TCAs) [18].”
BackgroundDepression and Its Phytopharmacotherapy—A Narrative Review
Dobrek, Ł., & Głowacka, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054772 · Cited by 198
Metadata
- Authors
- Wilson, E., & Lader, M.
- Affiliations
- King's College London (GB)
- Corresponding author
- Wilson, Emma
- ORCID
- Wilson, Emma
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2015-10-28
- Volume
- 5
- Issue
- 6
- Pages
- 357-368
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC4722507
- OpenAlex
- W2296227733
- Cited by
- 103
- References
- 52
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 6 · 2023: 7 · 2022: 10 · 2021: 8 · 2020: 14 · 2019: 14 · 2018: 15 · 2017: 12 · 2016: 4
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- King's College London
- Institute of Psychiatry, Psychology and Neuroscience, King’s College London
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- antidepressant discontinuation syndrome, antidepressant discontinuation, second-generation antidepressants, gradual tapering, fluoxetine, patient education, cognitive behavioral therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.